Business Wire

CA-GLOBALLOGIC

30.11.2021 13:30:05 CET | Business Wire | Press release

Share
GlobalLogic Announces Partnership with Cybereason to Develop Advanced, Intelligent Cyber Protection Solutions

GlobalLogic Inc. , a Hitachi Group Company and leader in Digital Engineering, today announced that it has been selected by Cybereason, the leader in operation-centric attack protection, to help develop its next-generation cyber security platform and services. Deployed by large enterprises, governments, and major cloud providers worldwide, Cybereason’s future-ready attack protection spans across endpoints, the enterprise, the cloud, and everywhere the defenders battle cyber criminals. The collaboration will draw on GlobalLogic’s broad and deep expertise in security and data management software across devices through to the cloud, including the integration of advanced artificial intelligence (AI).

The program is one of the largest won by GlobalLogic in this field to date. It requires quickly scaling to hundreds of specialized engineers supporting Cybereason’s development roadmap over the next year. This program scope highlights the market’s need for stronger, better cybersecurity as cloud use, network expansions and other technology usage continued their upward trend and surged during the pandemic.

“Cyber threats have become considerably more frequent and sophisticated in recent years. We’ve become dangerously more vulnerable in areas traditional security solutions could not adequately protect—the network and the cloud,” said Rajaram Radhakrishnan, CRO, GlobalLogic. “Having operated in the cybersecurity space for more than a decade, GlobalLogic has become adept at successfully responding to complex requirements. Cybereason is a premier example of a crucial innovator building disruptive defense solutions, redefining what government-grade protection can be. We are honored to now be a part of their team.”

Cybereason delivers the most comprehensive protection available on the market today, analyzing more than 23 trillion security-related events per week—five times the volume of any other market solution. Using its patented Malicious Operations (MalOps™) engine, Cybereason reveals the full attack story across every device, user identity, application, and cloud deployment. One of Cybereason’s key solutions delivering this capability is the company’s Extended Detection and Response (XDR) solution —a unified detection and response tool that thwarts malicious operations across the entire IT stack. XDR is one of the several advanced technologies that GlobalLogic’s team will help Cybereason develop and enhance through the partnership.

“Cybereason’ operation-centric security approach is helping defenders combat sophisticated and persistent threats to their organizations. While other companies have security analysts chasing alerts without offering valuable insight, Cybereason helps organizations around the world leverage our award-winning technology each day to outthink and outpace attackers,” said Sam Curry, Chief Security Officer, Cybereason. “GlobalLogic’s track record along with its responsiveness and collaborative approach to R&D stood out as major factors in finalizing our partnership. Together, we will deliver next-gen cyber defense solutions that will help technology users better control their sensitive data and operations—no matter where they reside.”

About GlobalLogic

GlobalLogic (www.globallogic.com ) is a leader in digital engineering. We help brands across the globe design and build innovative products, platforms, and digital experiences for the modern world. By integrating experience design, complex engineering, and data expertise – we help our clients imagine what’s possible and accelerate their transition into tomorrow’s digital businesses. Headquartered in Silicon Valley, GlobalLogic operates design studios and engineering centers around the world, extending our deep expertise to customers in the automotive, communications, financial services, healthcare and life sciences, manufacturing, media and entertainment, semiconductor, and technology industries. GlobalLogic is a Hitachi Group Company operating under Hitachi, Ltd. (TSE: 6501), which contributes to a sustainable society with a higher quality of life by driving innovation through data and technology as the Social Innovation Business.

About Cybereason

Cybereason (www.cybereason.com ) is the champion for today’s cyber defenders, providing operation-centric attack protection that unifies security from the endpoint to the enterprise, to everywhere the battle moves. The Cybereason Defense Platform combines the industry’s top-rated AI-powered detection and response (EDR and XDR), next-gen antivirus (NGAV), Anti-Ransomware Protection and Proactive Threat Hunting to deliver context-rich analysis of every stage of a MalOp™ (malicious operation). Cybereason is a privately held, international company headquartered in Boston with customers in more than 40 countries.

GlobalLogic is a trademark of GlobalLogic. All other brands, products or service names are or may be trademarks or service marks of their respective owners.

Link:

ClickThru

Social Media:

https://www.facebook.com/GlobalLogic/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye